Experimental Agent Shows Promise for Peyronie's Disease

Share this content:

Phase 3 studies assessing XIAFLEX (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie's disease (PD) show this agent may significantly improve quality of life.

Injections with this agent appear to significantly improve penile curvature deformity and improve appearance and pain.

John Schieszer has the latest on the story in today's Medical Minute.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters